Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including ion channels, GPCRs, and transporters. | Veneno Technologies is a Japan-origin deep-tech biotech company founded in 2020 and built around a proprietary Disulfide-Rich Peptide, or DRP, discovery platform. Based on scientific achievements originating from AIST, the company has established an integrated end-to-end system combining design, screening, functional evaluation, and production of DRPs through its proprietary Veneno Suite and PERISS platform. Veneno aims to create a new peptide modality for targets that have remained difficult to address with conventional small molecules or antibodies. The company’s core strength lies in its ability to translate the intrinsic biological advantages of naturally occurring DRPs into an industrial discovery engine. Because DRPs possess multiple disulfide bonds and a conformationally constrained structure, they can offer high stability, protease resistance, thermal robustness, and strong target selectivity. These properties make DRPs especially attractive for membrane proteins and other challenging target classes where conventional modalities often face limitations in selectivity, penetration, or functional control. Veneno is leveraging this differentiated biology to generate novel therapeutic candidates with the potential to open new mechanisms of action in previously hard-to-drug disease areas. Current Strategic Focus Areas 1) Ri-DRP drug discovery: Veneno is actively advancing Ri-DRP programs in which DRPs are conjugated with radioactive payloads, including alpha-emitting isotopes. By combining the high target selectivity and compact size of DRPs with radiopharmaceutical design, the company aims to enable precise tumor targeting and differentiated payload delivery beyond what is often achievable with conventional antibody-based radioconjugates or small-molecule radiopharmaceuticals. Ri-DRP represents a highly strategic direction for Veneno, particularly in oncology, where target-specific delivery, tissue distribution, and therapeutic precision are central to next-generation drug design. 2) Functional development of DRPs as next-generation antibody-like molecules: Veneno positions DRPs not simply as peptides, but as a next-generation functional modality that can complement and, in selected settings, outperform antibodies. The compact and highly structured nature of DRPs allows precise interaction with biologically important surfaces while maintaining strong stability and selectivity. This creates opportunities in areas where antibodies may be constrained by tissue penetration, epitope accessibility, or molecular size. Veneno is therefore developing DRPs as next-generation antibody-like agents for membrane proteins, complex interaction interfaces, and disease areas that require finely tuned molecular recognition. 3) DRP drug discovery for membrane proteins including ion channels, GPCRs, and transporters: Veneno’s discovery platform is particularly differentiated in the generation of functional DRPs against membrane proteins that have historically been difficult to drug. Through the proprietary PERISS method, the company can identify inhibitor, activator, and binder DRPs for ion channels, GPCRs, transporters, and related membrane targets. These target classes are biologically important across oncology, inflammation, pain, cardiometabolic disorders, and other major therapeutic areas, yet they remain challenging because small molecules can suffer from off-target effects and antibodies often have limited access to the relevant target surfaces. Veneno is using DRPs to bridge this gap and unlock first-in-class opportunities in membrane protein drug discovery. Through these three focus areas, Veneno Technologies is positioning DRPs as a scalable platform for next-generation therapeutics spanning membrane protein drug discovery, antibody-like functional molecules, and radiopharmaceutical innovation. At BIO International 2026, the company is seeking global collaboration opportunities including joint research, co-development, licensing, and strategic partnerships with pharmaceutical companies, biotech innovators, radiopharmaceutical developers, and research institutions.
SWISS Pavilion
Switzerland at BIO 2025: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2025 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2025. Join us in shaping the future of global health – the Swiss way. | Switzerland at BIO 2026: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2026 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2026. Join us in shaping the future of global health – the Swiss way. | Swissenviro was founded in 2015 by Urs Heutschi. It is a small, privately-owned company and the organizer of the SWISS Pavilion at international trade fairs for environmental technologies. With more than 20 years of experience, the international fair work is our area of expertise and forms the core of our work. The aim is to support export-orientated Swiss Cleantech SME to find buyers and business partners in international markets by encouraging international networking and direct B2B contacts on trade fairs and other events. By participation in a Joint Swiss Booth, the “SWISS Pavillon”, we are bringing together Swiss SMEs with professional trade visitors – potential future buyers, partners or suppliers. If desired, we gladly accompany and support the SME further on its business project resulting from this first customer contact. We closely work together with relevant Swiss environmental associations such as Cleantech Alps, VSA and Energie-Cluster. For our SWISS Pavilions we are supported by the MPK from “Switzerland Global Enterprise” (S-GE) and the “Swiss Federal Office for the Environment” (FOEN).
PreciGenome LLC
PreciGenome LLC, located in the heart of Silicon Valley in San Jose, California, is a leading innovator in developing state-of-the-art Lipid Nanoparticle (LNP) synthesis instruments and associated reagents, empowering researchers and pharmaceutical developers in their drug delivery endeavors. Our advanced microfluidic platforms enable precise and efficient LNP production, crucial for mRNA therapeutics and vaccine development. We offer comprehensive solutions that include both cutting-edge instrumentation, high-quality reagents and services, ensuring seamless integration and optimal results for our clients. At PreciGenome, we understand the critical nature of LNP formulation in modern drug delivery systems. Our technology delivers consistent particle size distribution and exceptional encapsulation efficiency, meeting the exacting standards required in pharmaceutical development. Whether you’re conducting early-stage research or scaling up for production, our systems provide the reliability and reproducibility essential for success in LNP-based therapeutics.
Pharmigene Inc
Established in 2005, Pharmigene Inc. is a leading biotechnology company specializing in pharmacogenomic testing. We hold exclusive global licenses from Academia Sinica for patents related to genetic testing for Warfarin and other critical medications such as Carbamazepine and Allopurinol. Leveraging these proprietary technologies, we have developed advanced diagnostic products and tools that have secured comprehensive technical patent certifications across numerous countries worldwide, including the USA, Europe, New Zealand, Australia, Japan, China, India, and Southeast Asia.Headquartered in Taiwan, Pharmigene operates a state-of-the-art R&D center and maintains stringent quality management systems. Our commitment to excellence is underscored by our certifications, including international ISO 13485, Taiwan QMS (GMP), and South Korea KGMP, ensuring the highest standards in medical device manufacturing and diagnostic solutions.
Molecule 46 s.r.o.
Molecule 46 is a biotech spin-off offering a unique patented technology for the separation of undamaged sperm to be used in human assisted reproduction and solve the infertility problem related to poor sperm quality. This technology is equally applicable to animal breeding strategies. The company brings an innovative approach with a strong IP position and robust scientific research. The new technology and clear regulatory pathway are strengthened by an internationally recognised founder with a strong academic track record and founder/market fit for a large and fast-growing market. Molecule 46 offers real social impact as well as endorsement from buyers and users. Our vision: Separation of winning sperm in alliance with nature. Our aim: Product certification and penetration to all the markets – European, American, and Global. | x
MilliporeSigma
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is committed to advancing cancer research. Our extensive portfolio of over 300,000 products supports the development of novel therapies, diagnostics, and prevention strategies. We offer solutions across key areas, including molecular tools, sample preparation, antibodies, cell culture, live cell analysis, biochemicals, and biomarker immunoassays. Cancer research is a multidisciplinary effort, and we provide integrated tools that accelerate progress at every stage—from basic to clinical research. Our molecular tools allow researchers to study cancer’s genetic and molecular foundations, while our high-quality antibodies enable the detection of proteins involved in cancer progression. MilliporeSigma also offers advanced sample preparation technologies for analyzing DNA, RNA, and proteins from tumor samples, and live cell analysis platforms for real-time insights into cellular behaviors and drug responses. Our biomarker immunoassays help identify cancer biomarkers and monitor treatment efficacy, supporting the development of early detection tests and personalized medicine. We are dedicated to empowering researchers with innovative solutions that help advance cancer prevention, detection, and treatment. MilliporeSigma is your trusted partner in tackling cancer biology complexities, accelerating breakthroughs, and realizing a future where cancer is more treatable and preventable. | As a leading science and technology company, we uniquely combine three specialized, innovation-driven businesses: Life Science, Healthcare, and Electronics. We utilize our multi-industry expertise to address a wide spectrum of global challenges. By supplying advanced scientific research and biotechnological manufacturing products, developing therapies for serious diseases, and providing high-performance materials for semiconductors and displays, we contribute to improving health, scientific progress, and technology for people around the world. | MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany. We are built to serve you in your drug development journey – as one trusted partner. Whether you need Millipore® CTDMO services, with decades of development, manufacturing, and testing expertise, to deliver a streamlined experience, or standalone industry-leading BioReliance® contract testing services and analytical development, we are built to serve you – to accelerate your milestones and breakthroughs. | MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, leverages over 35 years of CDMO experience and 75 years of contract testing services to redefine the industry CDMO model for today’s dynamic market needs. Our integrated Millipore® CTDMO Services offer expertise in development, manufacturing, contract testing, and technologies from pre-clinical to commercial stages, serving as a single experienced partner to accelerate your milestones and breakthroughs. With extensive experience in mRNA & LNP Formulation, ADC, Small Molecule, Biologics, and Viral Vector, we are dedicated to supporting your drug development journey as a trusted partner. Whether you seek a streamlined experience with a single partner or standalone industry-leading BioReliance® contract testing services and analytical development, we are committed to accelerating your milestones and breakthroughs while forging partnerships aimed at bringing breakthroughs to life to ultimately help patients. 2025 North America Advance Biotech Grant Award Ceremony Join us in the Start-up Stadium at 1:30pm, June 17th, to hear from our finalists and discover who will receive $258,000 in bioprocessing technologies, bioprocessing consulting services, contract testing services, and a full subscription to Emprove® Premium. The next round of applications will open in early 2026. | From the first spark of discovery to full-scale manufacturing, we stand beside you with the products, services, and expertise to help you move with speed and confidence. As a global leader in life science, MilliporeSigma supports innovators across biotech and pharma with 300,000+ products and comprehensive solutions all designed to help you progress from early research through process development, scale-up, and manufacturing. What you can explore with us: • Lab essentials and workflows to keep research moving day to day • Water purification systems for consistent lab performance • Raw and starting materials to support reliable manufacturing • Bioprocessing solutions and customized systems for your unique process needs • Ultrafiltration and downstream technologies to support scalable production • Contract testing and CDMO services to help you advance programs and meet quality requirements Whether you’re advancing a lead candidate, scaling a platform, or strengthening manufacturing readiness, we’ll connect you with experts who can help. | MilliporeSigma, the U.S. life science business of Merck KGaA, Darmstadt, Germany, partners with food safety teams to enable you to improve lab testing efficiencies with reliable products and services that meet ever changing regulations. It is through our collaborations that we can advance the safety and analysis of foods and beverages using trusted brands like Millipore® with microbiology solutions for hygiene, environmental monitoring & pathogen detection, Supelco® analytical solutions for analysis of food contamination and authenticity, Milli-Q® lab water solutions and Sigma Aldrich lab & production materials, including chemicals, inorganics & solvents throughout the supply chain, manufacturing and distribution. | MilliporeSigma is the U.S. life science business of Merck KGaA, Darmstadt, Germany. MilliporeSigma’s portfolio spans more than 300,000 products enabling scientific discovery. MilliporeSigma has customers in life science companies, university and government institutions, hospitals and industry. More than 1 million scientists and technologists use its products. The company is committed to solving the toughest problems in life science by collaborating with the global scientific community. | MilliporeSigma is the U.S. life science business of Merck KGaA, Darmstadt, Germany. With 19,000 employees and 72 manufacturing sites worldwide, MilliporeSigma’s portfolio spans more than 300,000 products enabling scientific discovery. MilliporeSigma has customers in life science companies, university and government institutions, hospitals and industry. More than 1 million scientists and technologists use its products. The company is committed to solving the toughest problems in life science by collaborating with the global scientific community. For more information, www.emdmillipore.com and www.sigma-aldrich.com.
Instant NanoBiosensors Co. Ltd
Instant NanoBiosensors (INB) is an innovative precision medicine company specializing in ultra-sensitive protein-based blood tests for Alzheimer’s disease and gene-based solutions for leukemia through its INLab NGS Solution. Revolutionizing Alzheimer’s Diagnostics Leveraging our proprietary Fiber Optic Particle Plasmon Resonance (FOPPR™) technology, we provide a non-invasive, rapid, and cost-effective solution for the early detection of Alzheimer’s-related biomarkers. Our technology enhances diagnostic accuracy, accelerates drug development, and supports personalized medicine applications for medical institutions and pharmaceutical companies. INB is the only point-of-care testing (POCT) platform on the market that enables end-to-end solutions—from antibody analysis to ultra-sensitive assay development. This platform has been adopted by the EU-funded TAuimMunE (TAME) project as a key training tool for PhD researchers. Current blood biomarker diagnostic methods are often expensive, centralized, and require specialized personnel to operate. INB’s solution addresses these limitations by making early Alzheimer’s detection more accessible and affordable. Our goal is to provide a highly accessible and precise diagnostic platform that enhances patient care and therapeutic outcomes worldwide. Leukemia Precision Medicine: INLab NGS Solution In leukemia diagnostics, INB has developed a comprehensive NGS Precision Medicine Solution that streamlines the entire workflow—from sample processing to final report generation—with fully integrated instruments, reagents, and software. We have extensive experience collaborating with National Taiwan University Hospital, working closely with hematology and oncology specialists to develop clinically relevant diagnostic reagents. Our solution currently serves nearly 70% of leukemia patients in Taiwan and has also been adopted by Yale Medical Center in the United States. Key Advantages of Our Solution ✅ Enhanced Accuracy and Efficiency: Our proprietary DimerOff™ technology minimizes primer dimer formation and sequencing noise, producing cleaner, more accurate sequencing data. This significantly improves sensitivity for detecting MDS/AML-related mutations, ensures higher clinical reliability, reduces sequencing costs by more than 50%, and shortens the turnaround time to just three days. ✅ MRD Detection & MPN Monitoring: Our solution enables precise monitoring of measurable residual disease (MRD) and myeloproliferative neoplasms (MPN), supporting long-term patient management and treatment adjustments. ✅ Customizable Panels for Specific Clinical Needs: We work closely with clinicians and researchers to develop NGS panels tailored to specific research and diagnostic requirements. Our flexible approach optimizes mutation detection, enhances patient stratification, and reduces operational costs for both research and clinical applications. Through continuous innovation and strategic partnerships, INB is committed to transforming precision medicine and improving patient outcomes worldwide. We Are Seeking Partnerships With: International Distributors interested in bringing our innovative diagnostic solutions to global markets. Biotech Companies looking for co-development opportunities in assay and panel development. Pharmaceutical Companies seeking companion diagnostics solutions to support targeted drug development. Hospitals & CROs aiming to establish a comprehensive precision medicine system within their organization. Scientists & Research Institutions interested in collaborative grant applications. If you are interested in collaborating with us, we welcome the opportunity to discuss how INB’s cutting-edge solutions can support your research, clinical, and commercial objectives.